Genentech maintained by Merrill Lynch at buy

Genentech Inc. was maintained by Merrill Lynch analyst Eric Ende at a buy rating with a price target on the stock of $103 per share following Genentech discontinuing enrollment into a phase II Avastin trial in platinum-refractory ovarian cancer due to an 11% incidence rate of gastrointestinal perforations. Genentech shares Monday were down $3.28, or 3.82%, at $82.55 on volume of 9,286,900 shares versus the three-month running average of 3,536,800 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.